alexa
Indianmoney.com Missed Call Number
 
Home News Dishman Pharma zooms 20% as US FDA approves its cancer drug

Read more interesting news from around the globe with Indianmoney App

Google Play
 
Get the Best Financial Advice on Demat and Trading Accounts Click Here
 
Dishman Pharma zooms 20% as US FDA approves its cancer drug

Dishman Pharma zooms 20% as US FDA approves its cancer drug

Tuesday, March 28, 2017, 9:57 AM

Dishman Pharmaceutical & Chemicals in Tuesday's pre-opening session is sizzling on the bourses, and the stock is up by 20% at Rs.278.70, as the company received US FDA approved cancer drug, Zejula for Tesaro Inc. Dishman Pharmaceutical & Chemicals is one of the API suppliers of Zejula capsules. The stock hit its 52-week high of Rs 278.20, and is locked at its upper circuit.
Read More

Learn to Save, Spend, Invest & Borrow Wisely with our Youtube Channel

Get It now!